Kei Kishimoto

Kei Kishimoto

Company: Selecta Biosciences

Job title: Chief Scientific Officer


Synergistic activity of IL-2 mutein with tolerogenic ImmTOR nanoparticles with leads to massive expansion of antigen-specific Tregs 2:00 pm

Engineered IL-2 molecules selective for the high affinity IL-2 receptor expressedon Tregs have been shown to non-selectively expand Tregs in vivo and are being developed for the treatment of autoimmune diseases We have developed tolerogenic nanoparticles that have been shown to induce antigen-specific immune tolerance and are in Phase 3 clinical trials in combination with…Read more

day: Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.